5Muddana V, Whitcomb DC, Papachristou GI. Current managementand novel insights in acute pancreatitis. Expert RevGastroenterol Hepatol, 2009, 3: 435-444.
6Chen CC, Wang SS,Lu RH,et al. Early changes of serumproinflammatory and anti-inflammatory cytokines afterendoscopic retrograde cholangiopancreatography. Pancreas,2003,26: 375-380.
7Cavallini G,Tittobello A,Fralloni L,et al. Gabexate for theprevention of pancreatic damage related to endoscopicretrograde cholangiopancreatography. Gabexate in digestiveendoscopy. N Engl J Med, 1996,335; 919-923.
8Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatinadministration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled,randomized clinical trial. Gastrointest Endosc,2002, 56:488-495.
9Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial ofsomatostatin and gabexate mesylate. Clin GastroenterolHepatol, 2004, 2; 713-718.
10Testoni PA, Mariani A,Masci E,et al. Frequency of post-ERCP pancreatitis in a single tertiary referral centre withoutand with routine prophylaxis with gabexate: a 6-year surveyand cost-effective analysis. Dig Liver Dis,2006,38 : 588-595.
